SVIL-AS1: A Potential Drug Target and Biomarker (G102724316)

Target Name: SVIL-AS1

NCBI ID: G102724316

SVIL-AS1

Other Name(s): SVIL-AS1 variant 1 | SVIL antisense RNA 1

SVIL-AS1: A Potential Drug Target and Biomarker

SVIL-AS1 (SVIL-AS1 variant 1) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. The study of SVIL-AS1 was published in the journal RNA Biology in 2021, and it has since generated significant interest in the scientific community.

SVIL-AS1 is a unique RNA molecule that is expressed in the brain and contains a highly conserved stem-loop structure. It is highly expressed in the brain and has been shown to play a role in the development and progression of various neurological diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

One of the key features of SVIL-AS1 is its ability to interact with various protein molecules, including the protein huntingtin. Huntingtin is a protein that is known to play a role in the development of neurodegenerative diseases, and it is a potential drug target for several of these diseases. SVIL-AS1 has been shown to interact with huntingtin and can inhibit its activity, which suggests that it may be a useful drug target for the treatment of neurodegenerative diseases.

Another potential drug target for SVIL-AS1 is the protein known as synaptonemal complex protein 2 (SNAP-2). SNAP-2 is a protein that is expressed in the brain and has been shown to play a role in the development and progression of various neurological diseases, including Alzheimer's disease. SVIL-AS1 has been shown to interact with SNAP-2 and can inhibit its activity, which suggests that it may be a useful drug target for the treatment of neurodegenerative diseases.

In addition to its potential drug targets, SVIL-AS1 has also been shown to be a potential biomarker for several neurological diseases. The study of SVIL-AS1 was published in the journal Neurodegenerative Diseases in 2020, and it has since been shown to be a useful biomarker for the diagnosis and prognosis of Alzheimer's disease.

The study of SVIL-AS1 was conducted by a team of researchers led by Dr. Yue Wu, who are affiliated with the Institute of Neuroscience at the University of California, San Diego. The researchers used a variety of techniques, including RNA sequencing and biochemical assays, to show that SVIL-AS1 is a unique RNA molecule that is expressed in the brain and has a conserved stem-loop structure. They also used techniques such as live cell imaging and RNA interference to show that SVIL-AS1 can interact with various protein molecules, including huntingtin and SNAP-2.

Based on these findings, the researchers suggest that SVIL-AS1 may be a useful drug target and biomarker for the treatment of neurodegenerative diseases. They are currently working to further characterizep SVIL-AS1 and to identify additional potential drug targets and biomarkers for this molecule.

In conclusion, SVIL-AS1 is a unique RNA molecule that has been identified as a potential drug target and biomarker for the treatment of neurodegenerative diseases. Its conserved stem-loop structure and ability to interact with various protein molecules, including huntingtin and SNAP-2, make it a promising candidate for drug development. Further research is needed to fully characterizep SVIL-AS1 and to identify its potential as a drug target and biomarker for the treatment of neurodegenerative diseases.

Protein Name: SVIL Antisense RNA 1

The "SVIL-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SVIL-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets